Therapeutic Implications of Vitamin D and Calcium in Overweight Women With Polycystic Ovary Syndrome

Gynecol Endocrinol. 2012 Dec;28(12):965-8. doi: 10.3109/09513590.2012.696753. Epub 2012 Jul 11.

Abstract

Objective: To assess effects of vitamin D and Calcium (Ca) on hormonal and metabolic milieu of polycystic ovary syndrome (PCOS).

Design: Single arm open label trial.

Methods: Twelve overweight and vitamin D deficient women with PCOS underwent a 2 hour oral glucose tolerance testing at baseline and following 3-month supplementation with vitamin D (daily dose of 3533 IU, increased to 8533 IU after the first five participants) and 530 mg elemental Ca daily.

Main outcome measures: Blood pressure (BP), plasma glucose, insulin, total testosterone (T) androstenedione (A), sex hormone binding globulin, lifestyle parameters were assessed at baseline and following 3-month intervention. Insulin resistance (IR) and area under the curve for glucose and insulin were computed; paired analyses were conducted.

Results: Improved serum 25OHD (p < 0.001) and reductions in total T (p = 0.036) and A (p = 0.090) levels were noted following 3-month supplementation, compared to baseline. Significant lowering in BP parameters was seen in participants with baseline BP ≥ 120/80 mmHg (n = 8) and in those with baseline serum 25OHD ≤20 ng/ml (n = 9). Parameters of glucose homeostasis and IR remained unchanged (p > 0.05).

Conclusions: Androgen and BP profiles improved followed three month intervention, suggesting therapeutic implications of vitamin D and Ca in overweight and vitamin D deficient women with PCOS.

Trial registration: ClinicalTrials.gov NCT00743574.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • 25-Hydroxyvitamin D 2 / blood
  • Adult
  • Body Mass Index
  • Calcifediol / blood
  • Calcium, Dietary / adverse effects
  • Calcium, Dietary / therapeutic use*
  • Cholecalciferol / administration & dosage
  • Cholecalciferol / adverse effects
  • Cholecalciferol / metabolism
  • Cholecalciferol / therapeutic use*
  • Cohort Studies
  • Dietary Supplements* / adverse effects
  • Ergocalciferols / administration & dosage
  • Ergocalciferols / adverse effects
  • Ergocalciferols / metabolism
  • Ergocalciferols / therapeutic use*
  • Female
  • Humans
  • Hyperandrogenism / etiology
  • Hyperandrogenism / prevention & control
  • Hypertension / etiology
  • Hypertension / prevention & control
  • Overweight / complications*
  • Patient Dropouts
  • Pilot Projects
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / diet therapy*
  • Polycystic Ovary Syndrome / metabolism
  • Polycystic Ovary Syndrome / physiopathology
  • Testosterone Congeners / blood
  • Vitamin D Deficiency / complications
  • Vitamin D Deficiency / diet therapy*
  • Young Adult

Substances

  • Calcium, Dietary
  • Ergocalciferols
  • Testosterone Congeners
  • Cholecalciferol
  • 25-Hydroxyvitamin D 2
  • Calcifediol

Associated data

  • ClinicalTrials.gov/NCT00743574